Exact Mass: 416.241
Exact Mass Matches: 416.241
Found 262 metabolites which its exact mass value is equals to given mass value 416.241
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Distigmine
ATC code: N07AA03
Ramipril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ramipril
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
CPA(18:2(9Z,12Z)/0:0)
cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.
Forasartan
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
Elarofiban
Glutamylleucylarginine
Zabicipril
AL 8810 Methyl ester
Distigmine
N - Nervous system > N07 - Other nervous system drugs > N07A - Parasympathomimetics > N07AA - Anticholinesterases D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D004791 - Enzyme Inhibitors
(5S,6E,10R)-5-beta-D-glucopyranosyloxy-3,10-dihydroxy-3,7,11-trimethyldodeca-1,5,11-triene|amarantholidoside II
(1S,4S,5R,7R,10R)-11,14-dihydroxyguai-3-one 11-O-beta-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-Dihydroxyguai-3-one 11-O-??-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-dihydroxyguaian-3-one 11-O-beta-D-glucopyranoside
(11S)-7-eudesmene-1beta,4beta,12-triol 1-O-beta-D-glucopyranose|iwayoside C
(5Z)-6-[5-(2-beta-D-glucopyranosyloxy-propan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol|shanyeside B
1-hydroperoxy-7,10-dihydroxybisabola-2,11-diene 7-beta-D-fucopyranoside
1-hydroperoxy-7,12-dihydroxybisabola-2,10-diene 7-beta-D-fucopyranoside
muurol-4-ene-1beta,3beta,10beta-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8R,8aS)-1,2,4a,5,6,7,8,8a-octahydro-8,8a-dihydroxy-3,8-dimethyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside
muurol-4-ene-1beta,3beta,15-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8S,8aR)-1,2,4a,5,6,7,8,8a-octahydro-8a-hydroxy-3-(hydroxymethyl)-8-methyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside
beta-methyl-15-hydroxymethylfaurinone-9-alpha-O-beta-D-glucoside|cupressusoside
(5Z)-6-[5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-O-beta-D-glucopyranoside
(5S,6E,9E)-5-beta-D-glucopyranosyloxy-3,11-dihydroxy-3,7,11-trimethyldodeca-1,6,9-triene|amarantholidoside I
1beta,6beta,9alpha-trihydroxy-trans-eudesm-3-ene-6-O-beta-D-glucopyranoside
1-acetyl-15,16-dimethoxy-aspidospermidine-17,21-diol|N-Acetyl-N-depropionyl-aspido-albinol
2alpha,7-dihydroxykessane 2-O-beta-D-glucopyranoside
Ala Ala Lys Gln
Ala Ala Gln Lys
Ala Lys Ala Gln
Ala Lys Gln Ala
Ala Gln Ala Lys
Ala Gln Lys Ala
Gly Gly Lys Arg
Gly Gly Arg Lys
Gly Lys Gly Arg
Gly Lys Asn Val
Gly Lys Arg Gly
Gly Lys Val Asn
Gly Asn Lys Val
Gly Asn Val Lys
Gly Arg Gly Lys
Gly Arg Lys Gly
Gly Val Lys Asn
Gly Val Asn Lys
Lys Ala Ala Gln
Lys Ala Gln Ala
Lys Gly Gly Arg
Lys Gly Asn Val
Lys Gly Arg Gly
Lys Gly Val Asn
Lys Asn Gly Val
Lys Asn Val Gly
Lys Gln Ala Ala
Lys Arg Gly Gly
Lys Val Gly Asn
Lys Val Asn Gly
Asn Gly Lys Val
Asn Gly Val Lys
Asn Lys Gly Val
Asn Lys Val Gly
Asn Val Gly Lys
Asn Val Lys Gly
Gln Ala Ala Lys
Gln Ala Lys Ala
Gln Lys Ala Ala
Arg Gly Gly Lys
Arg Gly Lys Gly
Arg Lys Gly Gly
Val Gly Lys Asn
Val Gly Asn Lys
Val Lys Gly Asn
Val Lys Asn Gly
Val Asn Gly Lys
Val Asn Lys Gly
Forasartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
1-BOC-4-[4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZOYL]-PIPERAZINE
tert-butyl 4-[[2-(5-amino-3-methyl-1H-pyrazol-4-yl)-6-methoxy-phe noxy]methyl]piperidine-1-carboxylate
tert-Butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperazine-1-carboxylate
Tonapofylline
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure[1][2].
Trecetilide
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
(2S,3aR,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
3-(6-ethoxynaphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
5-Benzyl-2,3-bis(4-methoxyphenyl)-1,4-dimethylpiperazine
1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)
3-[[(1,3-dimethyl-4-pyrazolyl)methyl-methylamino]methyl]-N-methyl-N-(phenylmethyl)-2-imidazo[1,2-a]pyridinecarboxamide
N-[(2S,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(1-oxo-2-phenylethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
1-(9Z,12Z,15Z)-octadecatrienylglycerone 3-phosphate
A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as (9Z,12Z,15Z)-octadecatrienyl.
1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)
A 1-alkylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-(9Z,12Z)-octadecadienylglycerone 3-phosphate; major species at pH 7.3.
(3s,6s,12s)-12-benzyl-5,11-dihydroxy-1,6,7-trimethyl-3-(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione
(2s,3r,4s,5s,6r)-2-{[(1s,2s,4ar,6r,7s,8ar)-1,6-dihydroxy-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3r,4s,5s,6r)-2-{[(1s,1ar,3ar,4s,7r,7as,7bs)-4-hydroxy-1-(hydroxymethyl)-1,7-dimethyl-octahydro-1ah-cyclopropa[a]naphthalen-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3s,4s,5s,6s)-2-{[(1r,1ar,4s,4as,7r,7as,7bs)-4-hydroxy-1-(hydroxymethyl)-1,7-dimethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
2-{[2-(6,7-dihydroxy-4a-methyl-8-methylidene-octahydronaphthalen-2-yl)propan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
2-{[1,6-dihydroxy-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1s,3as,4r,7r,8ar)-4-(hydroxymethyl)-1-methyl-7-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydro-1h-azulen-2-one
2-{[2,4-dihydroxy-4,8a-dimethyl-6-(prop-1-en-2-yl)-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3r,4s,5s,6r)-2-{[(3s,5s,6e,9e)-3,11-dihydroxy-3,7,11-trimethyldodeca-1,6,9-trien-5-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
10β,13,14-trihydroxyalloaromadendrane
{"Ingredient_id": "HBIN000059","Ingredient_name": "10\u03b2,13,14-trihydroxyalloaromadendrane","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC1CCC2C1C3C(C3(C)CO)CCC2(COC4C(C(C(C(O4)CO)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42560","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1s,4s,5r,7r,10r)-11,14-dihydroxyguai-3-one11-o-β-d-glucopyranoside
{"Ingredient_id": "HBIN003289","Ingredient_name": "(1s,4s,5r,7r,10r)-11,14-dihydroxyguai-3-one11-o-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC1C2CC(CCC(C2CC1=O)CO)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15108","TCMID_id": "5901","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
alatoside a
{"Ingredient_id": "HBIN015044","Ingredient_name": "alatoside a","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC(=C)C1CCC2(C(C1)C(CC(C2OC3C(C(C(C(O3)CO)O)O)O)O)(C)O)C","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "838","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11144190","DrugBank_id": "NA"}
atractyloside g
{"Ingredient_id": "HBIN017307","Ingredient_name": "atractyloside g","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC12CCC(CC1C(=C)C(C(C2)O)O)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14423","TCMID_id": "1979","TCMSP_id": "NA","TCM_ID_id": "6487","PubChem_id": "101831405","DrugBank_id": "NA"}